[go: up one dir, main page]

DK0526544T3 - Terapeutiske anvendelser af actinbindende forbindelser - Google Patents

Terapeutiske anvendelser af actinbindende forbindelser

Info

Publication number
DK0526544T3
DK0526544T3 DK91908685T DK91908685T DK0526544T3 DK 0526544 T3 DK0526544 T3 DK 0526544T3 DK 91908685 T DK91908685 T DK 91908685T DK 91908685 T DK91908685 T DK 91908685T DK 0526544 T3 DK0526544 T3 DK 0526544T3
Authority
DK
Denmark
Prior art keywords
actin
therapeutic uses
binding compounds
native
administration
Prior art date
Application number
DK91908685T
Other languages
English (en)
Inventor
Thomas P Stossel
Stuart E Lind
Paul A Janmey
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of DK0526544T3 publication Critical patent/DK0526544T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
DK91908685T 1990-04-11 1991-04-11 Terapeutiske anvendelser af actinbindende forbindelser DK0526544T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50721490A 1990-04-11 1990-04-11
PCT/US1991/002553 WO1991015770A1 (en) 1990-04-11 1991-04-11 Therapeutic uses of actin-binding compounds

Publications (1)

Publication Number Publication Date
DK0526544T3 true DK0526544T3 (da) 1999-06-21

Family

ID=24017703

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91908685T DK0526544T3 (da) 1990-04-11 1991-04-11 Terapeutiske anvendelser af actinbindende forbindelser

Country Status (10)

Country Link
US (2) US5260224A (da)
EP (1) EP0526544B1 (da)
JP (2) JP3616392B2 (da)
AT (1) ATE171625T1 (da)
AU (1) AU663050B2 (da)
CA (1) CA2080462C (da)
DE (1) DE69130289T2 (da)
DK (1) DK0526544T3 (da)
ES (1) ES2124702T3 (da)
WO (1) WO1991015770A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
DE69130289T2 (de) * 1990-04-11 1999-06-02 Brigham And Women's Hospital, Boston, Mass. Therapeutische verwendung von actin-bindenden verbindungen
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
JPH09510212A (ja) * 1994-03-11 1997-10-14 メルク エンド カンパニー インコーポレーテッド 肺疾患を処置するための組成物
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
GB2304047A (en) 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
USRE38490E1 (en) 1995-11-16 2004-04-06 Baylor College Of Medicine Method for identifying metastatic sequences
USRE38392E1 (en) 1996-01-30 2004-01-20 Baylor College Of Medicine Method for identifying metastatic sequences
ES2183220T3 (es) 1996-12-04 2003-03-16 Renovo Ltd Curacion de heridas y tratamientos de la fibrosis.
JP2002511748A (ja) * 1997-05-19 2002-04-16 カイロン コーポレイション アポトーシス誘導性ゲルゾリン配列
CA2308565A1 (en) * 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
US6545139B1 (en) 1998-03-13 2003-04-08 Baylor College Of Medicine DNA sequence encoding the p99 gene and kits for the detection of neoplasia
US6403766B1 (en) 1999-10-15 2002-06-11 Cornell Research Foundation, Inc. Human actin regulatory proteins and methods for detection, diagnosis and treatment of different stages of carcinogenesis
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
CA2456843A1 (en) * 2001-08-14 2003-02-27 Statens Serum Institut A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine
US7462491B2 (en) * 2002-01-31 2008-12-09 Baylor College Of Medicine Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin
US20030224464A1 (en) * 2002-01-31 2003-12-04 Baylor College Of Medicine Secreted caveolin as a marker for prostate cancer
AU2003226401A1 (en) * 2002-04-16 2003-11-03 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
US7301020B2 (en) * 2003-06-19 2007-11-27 Wisconsin Alumni Research Foundation Macrolide analogs and methods for identifying same
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
KR101314461B1 (ko) * 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
CA2578478A1 (en) * 2004-08-06 2006-02-16 National Jewish Medical And Research Center Product and process for inhibition of biofilm development
DK2001496T3 (da) 2006-03-15 2017-09-18 Brigham & Womens Hospital Inc Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme
HUE035980T2 (hu) 2006-03-15 2018-06-28 Brigham & Womens Hospital Inc Gelzolin alkalmazása szklerózis multiplex kezelésére és neurológiai betegségek diagnosztizálására
AU2008216147A1 (en) * 2007-02-15 2008-08-21 National Jewish Health Methods and compositions for the disruption of biofilms
PT2708603T (pt) * 2008-01-25 2017-07-20 The Brigham And Women`S Hospital Inc Utilizações em diagnóstico e terapia da gelsolina na insuficiência renal
US10112000B2 (en) 2010-07-08 2018-10-30 Asahi Kasei Medical Co., Ltd. Method for reducing amyloid beta concentration in blood

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03500166A (ja) * 1987-06-19 1991-01-17 シラキューズ　ユニバーシティ チトカラシンの精製方法および組成物
DE69130289T2 (de) * 1990-04-11 1999-06-02 Brigham And Women's Hospital, Boston, Mass. Therapeutische verwendung von actin-bindenden verbindungen
JPH09315440A (ja) * 1996-05-29 1997-12-09 Mitsui Petrochem Ind Ltd ラップフィルム収納箱

Also Published As

Publication number Publication date
DE69130289D1 (de) 1998-11-05
CA2080462C (en) 2004-10-26
US5508265A (en) 1996-04-16
EP0526544B1 (en) 1998-09-30
ES2124702T3 (es) 1999-02-16
AU7751691A (en) 1991-10-30
JP3616392B2 (ja) 2005-02-02
WO1991015770A1 (en) 1991-10-17
US5260224A (en) 1993-11-09
EP0526544A1 (en) 1993-02-10
DE69130289T2 (de) 1999-06-02
JP2005041881A (ja) 2005-02-17
EP0526544A4 (en) 1993-08-11
JPH05506034A (ja) 1993-09-02
ATE171625T1 (de) 1998-10-15
CA2080462A1 (en) 1991-10-12
AU663050B2 (en) 1995-09-28

Similar Documents

Publication Publication Date Title
DK0526544T3 (da) Terapeutiske anvendelser af actinbindende forbindelser
DE3650135D1 (de) Proteingewinnung.
ATE126706T1 (de) Hauttest und testkit für aids.
DE68924928D1 (de) Antikörper gegen latente Proteine von menschlichen Papillomavirus, diagnostische Systeme und Methoden.
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
ATE77056T1 (de) Antikoerperkomplexe von haptenmodifizierten diagnostischen oder therapeutischen mitteln.
NO873753L (no) Periodisk biologisk luftbehandlingsprosess og system for denne.
DE69410630D1 (de) Vorrichtung zur frühembryonalen in ovo injektion
DE69624150D1 (de) Lösung zur Konservierung von Organen oder Geweben oder Teilen davon aus Menschen oder Tieren
DK403384A (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
FR2660757B1 (fr) Procede d'identification ou de dosage de proteines et applications.
ATE168115T1 (de) In lösung bringen von proteinen in aktiver form
DK325289D0 (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
NO892269D0 (no) Ikke-hyperglykosylerte hepatitt b-virus-proteiner samt ekspresjons-"kassetter" og fremgangsmaate for fremstilling avproteinene.
DE3852625D1 (de) Vektoren und Verbindungen zur Expression von Zymogen-Formen von menschlichem Protein C.
FI881122A (fi) Menetelmä tyvikalvoproteiinien eristämiseksi ihmis- ja eläinkudoksista
FI844645A0 (fi) 1,7-difenyl-3-metylaza-7-cyan-8 -metyl-nonan foer anvaendning vid bekaempning av sjukdomar.
ES2109716T3 (es) Deteccion de proteinas termoestables de carne de rumiantes.
FI885025A (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
NO890245L (no) Isoxazoler med nootrop aktivitet.
DE3772047D1 (de) Pyrazin zur behandlung von haemodynamischen und metabolischen krankheiten.
DE3586795D1 (de) Absorptionsverbesserer fuer proteine.
NO871150D0 (no) Innretning for spesifikk, kvantitativ bestemmelse av proteiner og andre komponenter i blod og andre vaesker.
SE8902248D0 (sv) Anordning foer blodbehandling med hjaelp av elektromagnetiska faelt